A liposomal formulation of a local anesthetic shows promise for long-lasting pain relief with minimal toxicity, reports a research group led by Daniel S. Kohane of Harvard Medical School (Proc. Natl.

CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) today announced that it has developed a proprietary extended release depot formulation of the local anesthetic ropivacaine (F-93).

Researchers at Children's Hospital Boston have developed a slow-release anesthetic drug-delivery system that could potentially revolutionize treatment of pain during and after surgery, and may also ...

The root cause of local anesthetic-related neurosensory disturbances (NSDs) in dentistry has been unclear. But now a group of Danish researchers say it is neurotoxicity related to high-concentration ...

A new "proliposomal" preparation of the local anesthetic drug ropivacaine may provide a valuable new option for pain relief in some clinical situations, with key advantages over other types of ...

Medical researchers have developed a slow-release local anesthetic that could potentially revolutionize treatment of pain during and after surgery. By encapsulating anesthetics in fatty particles and ...

The FDA has notified healthcare professionals of 35 reports of chondrolysis in patients given continuous intra-articular infusions of local anesthetics (eg, bupivacaine, chlorprocaine, lidocaine, ...

What if you never had to administer anesthesia through a needle again? A recent study evaluated the possibility of using an electric current instead of a needle for local anesthesia during routine ...